Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
Study Details
Study Description
Brief Summary
The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Urinary tract infection (UTI) is the most common outpatient infection world-wide, and for people with spinal cord injury (SCI) and neurogenic bladder (NB), it is the most common infection, secondary condition, cause for emergency room visits, and infectious cause of hospitalization. Despite its prevalence, attempts to ameliorate UTI among people with SCI are stymied by long-standing diagnostic challenges which arise from evidence gaps around "gold standard" diagnostic tests (urinalysis and urine culture) that have lower sensitivity and specificity for UTI in this population. A high prevalence of chronic inflammation leading to persistence of white blood cells (WBC) in the urine confounds the utility of WBC count, pyuria, and leukocyte esterase as biomarkers for UTI; nitrites in urine indicate the presence of only specific (but not all) organisms, many of which are present to a greater extent in the urine of people with SCI; and people with SCI have a high prevalence of asymptomatic bacteriuria. These physiologic changes render the gold standard diagnostic tests less useful for identifying UTI in persons with SCI.
SA1. Estimate healthy, asymptomatic state variability of urine NGAL (uNGAL), white blood cells (uWBC), nitrite, cultivable bacteria, and the urinary microbiome.
SA2. Estimate the effect of intravesical LGG dose on urinary symptoms (primary outcome), uNGAL, uWBC, nitrites, cultivable bacteria, and the urine microbiome (secondary outcomes).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Low Dosage For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 ]LGG capsules and will repeat this process the following day ("Low" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion. |
Drug: Culturelle 10 Billion CFU Capsule
LGG® (Culturelle Probiotic with Lactobacillus RhamnosusGG, shown to produce the largest amount of antibacterial substances against pathogenic bacteria) will be used. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 or 4 LGG capsules (depending on randomization group) and will repeat this process the following day ("Low" dose) or twice daily for a total of four doses ("High" dose) according to randomization group.
Other Names:
|
| Active Comparator: High dosage For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses ("High" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion. |
Drug: Culturelle 10 Billion CFU Capsule
LGG® (Culturelle Probiotic with Lactobacillus RhamnosusGG, shown to produce the largest amount of antibacterial substances against pathogenic bacteria) will be used. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 or 4 LGG capsules (depending on randomization group) and will repeat this process the following day ("Low" dose) or twice daily for a total of four doses ("High" dose) according to randomization group.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Urinary Symptom Questionnaire for Neurogenic Bladder- Indwelling catheter [(SA 1) day of urine collection]
Will measure change in urinary symptoms for those that use an indwelling catheter. Higher score may mean worse outcomes. (local urine collection participants only)
- Urinary Symptom Questionnaire for Neurogenic Bladder- Indwelling catheter [(SA 1) day 1 post urine collection]
Will measure change in urinary symptoms for those that use an indwelling catheter. Higher score may mean worse outcomes. (local urine collection participants only)
- Urinary Symptom Questionnaire for Neurogenic Bladder- Indwelling catheter [(SA 1) day 2 post urine collection]
Will measure change in urinary symptoms for those that use an indwelling catheter. Higher score may mean worse outcomes. (local urine collection participants only)
- Urinary Symptom Questionnaire for Neurogenic Bladder- Indwelling catheter [(SA 1) day 3 post urine collection]
Will measure change in urinary symptoms for those that use an indwelling catheter. Higher score may mean worse outcomes. (local urine collection participants only)
- Urinary Symptom Questionnaire for Neurogenic Bladder- Indwelling catheter [(SA 2) Weekly up to 29 months]
Will measure change in urinary symptoms for those that use an indwelling catheter. Higher score may mean worse outcomes
- Urinary Symptom Questionnaire for Neurogenic Bladder- Indwelling catheter [(SA 2) day 1 of intervention (low or high dose)]
Will measure change in urinary symptoms for those that use an indwelling catheter. Higher score may mean worse outcomes. (local urine collection participants only)
- Urinary Symptom Questionnaire for Neurogenic Bladder- Indwelling catheter [(SA 2) day 2 of intervention (low or high dose)]
Will measure change in urinary symptoms for those that use an indwelling catheter. Higher score may mean worse outcomes
- Urinary Symptom Questionnaire for Neurogenic Bladder- Indwelling catheter [(SA 2) day 3 of intervention (low or high dose)]
Will measure change in urinary symptoms for those that use an indwelling catheter. Higher score may mean worse outcomes
- Urinary Symptom Questionnaire for Neurogenic Bladder- Indwelling catheter [(SA 2) day 4 of intervention (low or high dose)]
Will measure change in urinary symptoms for those that use an indwelling catheter. Higher score may mean worse outcomes
- Urinary Symptom Questionnaire for Neurogenic Bladder- Indwelling catheter [(SA 2) day 5 of intervention (high dose only)]
Will measure change in urinary symptoms for those that use an indwelling catheter. Higher score may mean worse outcomes
- Urinary Symptom Questionnaire for Neurogenic Bladder- Indwelling catheter [(SA 2) 24-48 hours after intervention completion]
Will measure change in urinary symptoms for those that use an indwelling catheter. Higher score may mean worse outcomes. (local urine collection participants only)
- Change in Urine white blood cell count [(SA 1) day 1 post urine collection]
urinalysis. (local urine collection participants only)
- Change in Urine white blood cell count [(SA 1) day 14 post urine collection]
urinalysis. (local urine collection participants only)
- Change in Urine white blood cell count [(SA 2) day 1 of intervention]
urinalysis. (local urine collection participants only)
- Change in Urine white blood cell count [(SA 2) 24-48 hours after intervention completion]
urinalysis. (local urine collection participants only)
- Change in Urine Nitrite [(SA 1) day 1 post urine collection]
urinalysis. (local urine collection participants only)
- Change in Urine Nitrite [(SA 1) day 14 post urine collection]
urinalysis. (local urine collection participants only)
- Change in Urine Nitrite [(SA 2) day 1 of intervention]
urinalysis. (local urine collection participants only)
- Change in Urine Nitrite [(SA 2) 24-48 hours after intervention completion]
urinalysis. (local urine collection participants only)
- Change in Urine NGAL [(SA 1) day 1 post urine collection]
Urine NGAL. (local urine collection participants only)
- Change in Urine NGAL [(SA 1) day 14 post urine collection]
Urine NGAL. (local urine collection participants only)
- Change in Urine NGAL [(SA 2) day 1 of intervention]
Urine NGAL. (local urine collection participants only)
- Change in Urine NGAL [(SA 2) 24-48 hours after intervention completion]
Urine NGAL. (local urine collection participants only)
- Change in Cultivable Bacteria [(SA 1) day 1 post urine collection]
urine culture. (local urine collection participants only)
- Change in Cultivable Bacteria [(SA 1) day 14 post urine collection]
urine culture. (local urine collection participants only)
- Change in Cultivable Bacteria [(SA 2) day 1 of intervention]
urine culture. (local urine collection participants only)
- Change in Cultivable Bacteria [(SA 2) 24-48 hours after intervention completion]
urine culture. (local urine collection participants only)
- Change in Urine microbiome composition and function [(SA 1) day 1 post urine collection]
Next generation sequencing for microbiome composition. (local urine collection participants only)
- Change in Urine microbiome composition and function [(SA 1) day 14 post urine collection]
Next generation sequencing for microbiome composition. (local urine collection participants only)
- Change in Urine microbiome composition and function [(SA 2) day 1 of intervention]
Next generation sequencing for microbiome composition. (local urine collection participants only)
- Change in Urine microbiome composition and function [(SA 2) 24-48 hours after intervention completion]
Next generation sequencing for microbiome composition. (local urine collection participants only)
- NINDS Medical History CDE: [Baseline]
A brief medical history using body system categories
- Medical History Form [Baseline]
Medical history of participant
- International SCI Lower Urinary Tract Function Basic Data Set [Baseline]
A tool to describe urinary tract impairment, awareness of need to empty the bladder, main bladder emptying method, medications used for bladder management, surgeries, and change in urinary symptoms in the past year.
- NINDS Prior and Concomitant Medications CDE [Baseline]
Contains whether or not the participant is taking a medication during the study protocol, name of medication, reason for medication, medication dose, frequency, start and end dates, and free text
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Neurogenic bladder for at least 6 months;
-
Utilizing indwelling catheterization for bladder management;
-
Women must be premenopausal and not currently menstruating;
-
Community dwelling
-
physical disability
Exclusion Criteria:
-
Use of prophylactic antibiotics;
-
Instillation of intravesical antimicrobials to prevent UTI;
-
Psychologic or psychiatric conditions influencing the ability to follow instructions;
-
Use of oral or IV antibiotics within the past 2 weeks;
-
Sexual activity within the previous 72 hours;
-
Participation in another study with which results could be confounded.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | MedStar National Rehabilitation Hospital | Washington | District of Columbia | United States | 20010 |
Sponsors and Collaborators
- Medstar Health Research Institute
- Children's National Research Institute
Investigators
- Principal Investigator: Suzanne Groah, MD, MSPH, MedStar National Rehabilitation Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STUDY00001782